Print this page
-
A Phase II/III Randomized Study of R-miniCHOP With or Without Oral Azacitidine (CC-486) in Participants Age 75 years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements.
Protocol: 012103Principal Investigator:
- Matthew Matasar (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase Ib, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous Glofitamab Following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
Protocol: 012107Principal Investigator:
- Matthew Matasar (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Randomized Phase 3 Trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma.
Protocol: 112105Principal Investigator:
- Archana Sharma DO (Rutgers University)
Applicable Disease Sites: Lymphoid Leukemia
Any Site -
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Leukemia, not otherwise specified -
A Long-Term Study for Participants Previously Treated With Ciltacabtagene Autoleucel.
Protocol: 012204Principal Investigator:
- Matthew Matasar (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Multiple Myeloma -
Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia.
Protocol: 112002Principal Investigator:
- Peter Cole M.D. (Rutgers University)
Applicable Disease Sites: Leukemia, not otherwise specified